ArticleResearch square2025
Effects of Diminished Cerebrospinal Fluid Flow in the Spinal Canal on Amyloid Pathophysiology in Vervet Monkeys.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: Translational models using nonhuman primates provide valuable insights into the pathological changes associated with human brain aging. This study investigates the vervet monkey ( Methods: To test the hypothesis that diminished CSF perfusion in the central nervous system contributes to AD pathophysiology, we quantified CSF flow dynamics (i.e. stroke volume, amplitude and peak flow) in the spinal canal via phase-contrast MRI and examined its association with age and AD fluid biomarkers in 16 female vervet monkeys aged from 10 to 27 years. Results: Strong negative correlations were observed between CSF flow metrics across the cardiac cycle and age (ρ = -0.68 to -0.83), and positive correlations were found between CSF flow metrics and CSF Aβ42/40 ratio (ρ = 0.67 to 0.84), while plasma biomarkers showed no correlation with CSF flow metrics. Age-adjusted analyses demonstrated moderate correlations between CSF flow and CSF Aβ42/40 ratio (ρ = 0.45 to 0.75). Conclusion: These findings suggest that diminished CSF flow dynamics in the central nervous system could serve as a valuable imaging marker for impaired amyloid clearance, reflecting early-stage AD-like pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.